Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Mar 11;14(1):41.
doi: 10.1186/s13014-019-1245-9.

Risk factors to identify patients who may not benefit from whole brain irradiation for brain metastases - a single institution analysis

Rebecca Buecker  1 , Zhen-Yu Hong  2 , Xiao-Mei Liu  2 , Gert Jaenke  1 , Ping Lu  2 , Ulrich Schaefer  3
Affiliations
Clinical Trial

Risk factors to identify patients who may not benefit from whole brain irradiation for brain metastases - a single institution analysis

Rebecca Buecker et al. Radiat Oncol. .

Abstract

Background: Radiotherapy plays a major role in the management of brain metastases. This study aimed to identify the subset of patients with multiple brain metastases who may not benefit from whole brain irradiation (WBI) due to a short survival time regardless of treatment.

Methods: We analyzed a total of 339 patient records with brain metastases treated with whole brain radiotherapy from January 2009 to January 2016. External beam radiotherapy techniques were used to deliver 33 Gy in 11 fractions (4 fractions per week) to the whole brain. Eight clinical factors with a potential influence on survival were investigated using the Kaplan-Meier method. All factors with a P < 0.05 in univariate analysis were entered into multivariate analysis using Cox regression.

Results: In the present series of 339 patients, median survival time was 2.5 months (M; range, 0-61 months). Four risk factors Karnofsky Performance Score (KPS) < 70, age > 70, > 3 of metastases intracranial, uncontrolled primary tumor) were identified that were significant and negatively correlated with median survival time. Patients with no risk factors had a median survival of 4.7 M; one risk factor, 2.5 M; two risk factors, 2.3 M; and 3-4 risk factors, 0.4 M (p < 0.00001).

Conclusions: Patients with identified risk factors might have a negatively impacted overall survival after WBI. Accordingly, patients who will not benefit from WBI can be easily predicted if they have 3-4 of these risk factors.

Keywords: Brain metastasis; Median survival; Risk factor; Whole brain irradiation.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing of interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Overall survival after WBI. Of the 339 patients, the survival time was 0–61 months with a median survival time of 2.5 months
Fig. 2
Fig. 2
Odd ratio for overall survival with 95% confidence intervals. Odd ratio for overall survival: Risk factors with 95% confidence intervals
Fig. 3
Fig. 3
Overall survival according to the sum of risk factors from Fig. 2. Overall survival according to the sum of risk factors from Fig. 2: Black = 0, blue = 1, red = 2, green 3–4 risk factors
See this image and copyright information in PMC

References

    1. Rades D, Bohlen G, Lohynska R, et al. Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP) Strahlenther Onkol. 2007;183(11):631–636. doi: 10.1007/s00066-007-1763-5. - DOI - PubMed
    1. Rades D, Dunst J, Schild SE. A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol. 2008;184(5):251–255. doi: 10.1007/s00066-008-1831-5. - DOI - PubMed
    1. Sundstrom JT, Minn H, Lertola KK, et al. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med. 1998;30(3):296–299. doi: 10.3109/07853899809005858. - DOI - PubMed
    1. Pease NJ, Edwards A, Moss LJ. Effectiveness of whole brain radiotherapy in the treatment of brain metastases: a systematic review. Palliat Med. 2005;19(4):288–299. doi: 10.1191/0269216305pm1017oa. - DOI - PubMed
    1. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–751. doi: 10.1016/S0360-3016(96)00619-0. - DOI - PubMed

Publication types